NRG
TTNP

Nemes Rush Group’s Titan Pharmaceuticals TTNP Stock Holding History

Nemes Rush Group’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$5 – 1007
2025
Q3 		$5 Hold
1
– – ﹤0.01% 677
2025
Q2 		$4 Hold
1
– – ﹤0.01% 720
2025
Q1 		$4 Hold
1
– – ﹤0.01% 705
2024
Q4 		$3 Hold
1
– – ﹤0.01% 727
2024
Q3 		$7 Hold
1
– – ﹤0.01% 607
2024
Q2 		$6 Hold
1
– – ﹤0.01% 605
2024
Q1 		$8 Buy
+1
New +$7 ﹤0.01% 665
2023
Q4 		– Hold
0
– -$1 – 689
2023
Q3 		– Hold
0
– – – 658
2023
Q2 		– Hold
0
– – – 677

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Nemes Rush Group's TTNP Position: Q4 2025 in Review

Nemes Rush Group sold out of Titan Pharmaceuticals (TTNP) in Q4 2025, closing a stake of 1 share — an estimated $5 sold.

Nemes Rush Group first reported a position in TTNP in Q1 2024 and held it in 7 quarters. The position peaked at $8 in Q1 2024. 4 funds tracked by Wall St. Rank hold TTNP as of Q4 2025.

  • Nemes Rush Group reported no remaining Titan Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Nemes Rush Group sold 1 Titan Pharmaceuticals share in Q4 2025, an estimated $5.
  • Nemes Rush Group first reported a position in Titan Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Nemes Rush Group's Titan Pharmaceuticals position peaked at $8 in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2025.

Based on Nemes Rush Group's 13F filing for Q4 2025, filed 11 Feb 2026.